BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28782639)

  • 21. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
    Naso JR; Churg A
    Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
    Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
    Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
    Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
    Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
    Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.
    Hurtuk MG; Carbone M
    Anticancer Res; 2004; 24(5B):3097-102. PubMed ID: 15510595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
    Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
    Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR; Tsuji S; Churg A
    Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.
    Marchevsky AM; Khoor A; Walts AE; Nicholson AG; Zhang YZ; Roggli V; Carney J; Roden AC; Tazelaar HD; Larsen BT; LeStang N; Chirieac LR; Klebe S; Tsao MS; De Perrot M; Pierre A; Hwang DM; Hung YP; Mino-Kenudson M; Travis W; Sauter J; Beasley MB; Galateau-Sallé F
    Mod Pathol; 2020 Feb; 33(2):281-296. PubMed ID: 31485011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.
    Dacic S; Le Stang N; Husain A; Weynand B; Beasley MB; Butnor K; Chapel D; Gibbs A; Klebe S; Lantuejoul S; Roden AC; Roggli V; Tazelaar H; Vignaud JM; Galateau-Sallé F
    Mod Pathol; 2020 Feb; 33(2):255-262. PubMed ID: 31273316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
    Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
    Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
    Derakhshan F; Ionescu D; Cheung S; Churg A
    Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
    Johansson L; Lindén CJ
    Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
    Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases.
    Weissferdt A; Kalhor N; Rodriguez Canales J; Fujimoto J; Wistuba II; Moran CA
    Hum Pathol; 2017 Jan; 59():1-9. PubMed ID: 27569293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.